BarrettNET—a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma

• DOI: 10.1093/dote/doz024
• Publication Date: 2019-04-24T17:05:33Z
• Authors: Maria Wiethaler; Julia Slotta-Husp...; Anna Brandtner; Julia Horstmann; Frederik Wein; Theresa Baumeister; Nikole Radani; Sophie Gerland; Akanksha Anand; Sebastian Lange; Melissa Schmidt; Klaus-Peter Janssen; Anja Conrad; Widya Johannes; Konstantin Strauch; Anne S Quante; Birgit Linkohr; Klaus A Kuhn; Rainer Blaser; Andreas Lehmann; Florian Kohlmayer; Wilko Weichert; Roland M Schmid; Karl-Friedrich Be...; Michael Quante
• Keywords: Barrett's esophagus; Esophageal adenocarcinoma

SUMMARY Risk stratification in patients with Barrett's esophagus (BE) to prevent the development of esophageal adenocarcinoma (EAC) is an unsolved task. The incidence EAC and BE increasing are still at unknown risk. BarrettNET ongoing multicenter prospective cohort study initiated identify validate molecular clinical biomarkers that allow a more personalized surveillance strategy for BE. For participants recruited 20 centers throughout Germany, be followed progression dysplasia (low-grade or high-grade dysplasia) >10 years. instruments comprise self-administered epidemiological information (containing data on demographics, lifestyle factors, health), as well biological specimens, i.e., blood-based samples, tissue biopsies, feces saliva samples. In follow-up visits according individual plan participants, sample collection repeated. standardized processing specimen guarantee highest quality. Via mobile accessible database, documentation inclusion, data, pathological disease status recorded subsequently. Currently registry includes 560 (23.1% women 76.9% men, aged 22–92 years) median 951 days. Both design size offer advantage answering research questions regarding potential causes from EAC. Here all integrated methods materials presented reviewed introduce this valuable German registry.